ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effects — according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando. Dr Abdenour Nabid from Sherbrooke University in Quebec gave Peter Goodwin the details.[audio:https://www.audiomedica.com/podcasting/oncology/130310AbdenourNabidAJOPODCASTLoRes.mp3]
You may also like...
ASCO Audio Journal of Oncology – May 15th, 2006 14 May, 2006 Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer 17 Jan, 2007 ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 16 Jun, 2007 Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer 27 Jan, 2008
- Previous story Low risk localized prostate cancer: no harm from waiting!
- Next story Low risk localized prostate cancer: no harm from waiting!
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014